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Background: Given the observed association between smoking, inflammation and airway
hyperresponsiveness (AHR) one may predict that smoking cessation may improve AHR.
However, only a few studies have investigated the effect of smoking on AHR and their
results appear to be conflicting depending on the stimulus used in their bronchoprovoca-
tion protocol. The aim of the current study was to compare changes in AHR between direct
(methacholine (Mch)) and indirect (adenosine 50monophosphate (AMP)) stimuli before and
at different time points after smoking cessation in smokers with allergic rhinitis
(7asthma).
Methods: We have prospectively studied changes in AHR to inhaled Mch and AMP in
smokers with allergic rhinitis (7asthma), before and at 6 and 12 months after smoking
cessation.
Results: It was found that 28% (16/57) of the participants had quit smoking by the end
of the study. No significant change in AHR was observed in smoking cessation failures.
A significant improvement in AHR to AMP but not Mch was observed 6 months after smoking
cessation in quitters; a 1.2 doubling concentrations change in PC20 AMP was measured
whereas only a 0.4 doubling concentrations change was observed for PC20 Mch. However,
after 12 months smoking cessation the improvement in AHR became significant for both
AMP and Mch, their dose–response curves being displaced to the right to a similar extent
(1.4 and 1.1 doubling concentrations for AMP and Mch, respectively).Elsevier Ltd. All rights reserved.
7594506; fax: +39 095 330707.
(P. Caponnetto).
iversity of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK.
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Changes in AHR after smoking cessation 257Conclusion: Smoking cessation can improve AHR in smokers who quit with a 6 months
improvement being reported for the airways response to AMP but not Mch. AMP challenge
may detect earlier changes in AHR in smokers during smoking cessation.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Non-specific airway hyperresponsiveness (AHR), the abnor-
mal increase in airflow limitation following exposure to non-
allergic stimuli, is known to be associated with several
chronic inflammatory conditions of the airways, including
asthma and rhinitis.1,2 AHR can be used to aid in diagnosis
and characterization of individuals with inflammatory air-
way disease and appears to be a distinctive indicator of
disease severity and disease progression.3–5 Occurrence of
non-specific AHR in individuals with asthma or rhinitis is
likely to be a sign of ongoing inflammation in the lower
airways.6–8 Cigarette smoke induces inflammatory changes
in the respiratory tract of individuals who smoke and
particularly in those with diseased airways9; as a result
cigarette smoke may further contribute to non-specific AHR.
Given the observed association between smoking, inflam-
mation and AHR, one may predict that smoking cessation
(SC) may ameliorate AHR. Nevertheless, improvement in
AHR may be strictly dependent on the stimulus used in
bronchoprovocation protocols. AHR to indirect stimuli, such
as inhaled adenosine 50-monophosphate (AMP), appear to
better reflect changes in airway inflammation than do AHR
to direct bronchial provocants, such as methacholine
(Mch).10–12 This may lead to the speculation that bronchial
provocation with inhaled AMP could provide a better tool for
detecting inflammatory changes also in the context of a SC
trial. In a cross sectional comparative study of active
smokers and ex-smokers with COPD, active smokers ex-
hibited a similar sensitivity to inhaled AMP and Mch whereas
in ex-smokers much lower airway sensitivity to AMP was
observed.13 Differences in the level of AHR to AMP and Mch
have also been detected when asthmatic smokers were
compared to asthmatic nonsmokers.14 These cross-sectional
studies appear to suggest that SC ameliorates AHR to a
different extent depending on the specific bronchostimulant
used. However, detailed longitudinal studies are not avail-
able to confirm these cross-sectional findings. The aim of the
current study was to compare changes in non-specific AHR to
inhaled AMP and Mch before and at different time points
after SC. As AHR is known to be frequently reported in
subjects with allergic rhinitis and asthma, changes in AHR to
inhaled AMP and Mch after quitting were investigated in
smokers with seasonal allergic rhinitis with or without
asthma. In addition, we have prospectively evaluated
changes in lung function.Methods and materials
A total of 57 active smokers (415 cigarettes/day, for at
least 5 yrs) with seasonal allergic rhinitis with or without
asthma (age range 22–61), willing to quit, and with
documented airways sensitivity to AMP (PC20o800mg/ml)and Mch (PC20o16mg/ml) were entered in the study. All
were atopic, as defined by at least one positive skin prick
test reaction (43mm wheal response) to a panel of 10
common allergens (including Parietaria judaica, Dermato-
phagoides pteronyssinus, Dermatophagoides farinae, Olea
europea, grass pollen, orchard, cypressus, alternaria,
perennial rye, and cat allergen). Inclusion criteria com-
prised stable rhinitis/asthma (having had no exacerbation or
respiratory tract infection in the previous 6 weeks) and
baseline FEV1X70% predicted. Subjects had never used
systemic or topical corticosteroids before or had stopped
their use at least 2 months before entry into the study.
Throughout the study, only short acting inhaled b2-adrenor-
eceptor agonists and oral antihistamines were allowed for
relief of asthma/rhinitis symptoms (bronchodilators were
withheld for 8 h before each bronchial challenge visits;
antihistamines were not taken at least 3 days before each
bronchial challenge visits). The study protocol was approved
by the local hospital’s ethics committee, and written
informed consent was obtained for each patient.
This prospective study was designed as a 12-month
longitudinal, observational, clinical trial to investigate the
effect of quitting smoking on airway responsiveness to
inhaled AMP and Mch in smokers with seasonal allergic
rhinitis with or without asthma with documented AHR to
both agonists.
Measurements of the AHR to inhaled AMP and Mch were
carried out at baseline, at 6 and at 12 months after SC both
in those smokers who will be still abstinent at time of
sampling (quitters) and those who will fail to quit smoking
(SC failures). SC failures were used in this study as a smoking
reference group for comparison between groups after
smoking cessation. The study comprised the following visits
(Figure 1).Baseline/screening visit
Subjects undertook concentration–response studies with
inhaled Mch first followed by AMP challenge 2–3 h later.
The order of inhalation challenges was kept identical for all
subjects throughout the 12 months of study. This visit took
place outside the pollen season. Lung function (FEV1, flow
volume curve (FVC)) was assessed by spirometry. Evaluation
of small airways function was carried out by deriving from
the FVC taken at baseline the forced expiratory flow at the
middle half of the FVC (FEF25–75%). A detailed smoking
history was taken and individual pack-years calculated
(pack-years ¼ [total number of years of cigarettes con-
sumption] [total number of cigarettes smoked per day]/
20) together with scoring of their level of nicotine
dependence by means of a standard FTND questionnaire.15
Concentration of carbon monoxide in expired breath (eCO)
was also measured (Micro CO-Micro Medical Ltd., Rochester,
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Figure 1 Schematic diagram of the study design. Smokers willing to quit took part in a longitudinal study to assess changes in AHR to
direct (MCh) and indirect (AMP) stimuli at baseline and prospectively at 6 and 12 months after smoking cessation. Smoking cessation
failures are used as smoking reference group for the change in AHR to MCh and AMP after smoking cessation. eCO: carbon monoxide in
expired breath; MCh: methacholine; AMP: adenosine 50-monophosphate.
G. Piccillo et al.258UK) and a small hair sample taken for nicotine assessment
(about 25mg). Subjects were invited to take part in a SC
program; they were instructed on how to prepare to stop
smoking and to set a quit date, prescribed with medications
tailored to their individual needs, and booked for their first
follow-up visit within 7 days.
Follow-up visits
Between the baseline visit and the 6 month visit, SC
counselling and treatment were offered over several brief
appointments (5–8 appointments within the first 8 weeks of
the SC programme). On each occasions, participants
reported the quantity of medication used and their smoking
status. eCO readings were taken at each appointment.
Six months visit
Six (71; to allow for this visit to take place outside the
pollen season) months after admission, an eCO reading was
recorded and a further hair sample taken. Subjects under-
took concentration–response studies with inhaled Mch first
followed by AMP challenge 2–3 h later. As before, the order
of inhalation challenges was kept identical. FEV1, FVC and
FEF25–75% were noted.
Twelve months visit
Twelve (71; to allow for this visit to take place outside the
pollen season) months after admission, a final eCO reading
and hair sample were taken. Similar to the 6 month visit,
subjects undertook concentration–response studies with
inhaled Mch first followed by AMP challenge 2–3 h later
and spirometry parameters (FEV1, FVC, and FEF25–75%) were
recorded.
The SC strategies/interventions currently in use at the
University of Catania for smokers taking part in the study
follow the clinical practice guidelines on SC of the AHCPR16
and was specifically modified to facilitate subjects’ partici-pation and to improve SC specialists’ performance. Typi-
cally, our SC program has the duration of 4–6 weeks.
Participants are instructed on how to prepare to stop
smoking and encouraged to set a ‘‘quit date’’ right away.
A variety of methods are employed including motivational
counselling, nicotine replacement therapy (NRT) and the
prescription of medications, with each intervention being
tailored to individual needs. Treatment management is
designed to match patients’ level of nicotine dependence
and dose, to control for anxiety and depression, and takes
into account the level of motivation. In general, pharmaco-
logical treatment includes the use of assorted NRT in
association with bupropion (300mg/day). The first follow-
up visit is timed within a few days from the established
‘‘quit date’’. Further SC counselling by motivational inter-
viewing is offered at each following visits (usually up to 6–8
weeks). Abstinence from cigarette smoking is objectively
assessed by measuring the concentration of eCO at each
appointment and by assaying the level of hair nicotine at 6
and 12 months after admission in the SC programme.
Participants who had given up smoking with a eCO con-
centration ofo5 ppm at each follow up appointment and/or
low levels (o5 ng/mg hair—this cutoff threshold was
derived from the data of a random group of 50 healthy long
life non smokers considering their median [inter-quartile
range] nicotine levels was 2.60 [1.51; 3.95] ng/mg hair) of
hair nicotine at 6 and 12 months after SC were defined as
quitters. Those smokers who failed to meet these criteria
were categorized as SC failures.
Samples were collected by cutting hair from the base of
the scalp behind the ear and were stored in paper
envelopes. About 1 cm of hair was then cut from the end
closest to the scalp using a scalpel swabbed with methanol.
Hair was handled with tweezers and fresh paper was used
underneath each sample. Duplicate samples of about 2–4mg
were weighed into capped 10-ml polypropylene tubes and
then washed for 90min in 2ml of dichloromethane at room
temperature. The dichloromethane was aspirated off using a
polypropylene transfer pipette and samples dried briefly at
50 1C. The hair was then digested at 50 1C overnight in 2ml
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cool and 50 ml of 750 mg/l 2-phenylimidazole was added as an
internal standard. Nicotine was then extracted into 4ml of
diethyl ether in the capped tube by vortexing for 40–60 s.
After transferring the ether to a second 10-ml polypropylene
tube containing 100 ml of 0.1% (v/v) HCl in methanol, the
ether was evaporated to dryness under a stream of air at
40 1C. The extract was then injected into the gas cromatho-
graphy instrument (Trace GC Ultra by Thermo Electron
Corporation) with a nitrogen phosphorus detector (NPD).
The sample was volatilized at the injection port and eluted
through a non-polar capillary column (SPB-5 by Supelco)
under increasing temperature. As the sample moved through
the column, various components were separated due to
their affinity for the stationary phase of the column and
could be identified by their distinct retention time. Samples
for use as quality controls were acquired from non-smoking
volunteers when they had routine haircuts. The samples
were cut into 0.5–1.0 cm lengths and then randomised by
mixing. These samples were run randomly throughout
batches. A standard extracted without hair was also run in
each batch to specifically check the extraction and
chromatographic part of the procedure. With this method
the estimated lower limit of detection is 0.2 ng nicotine/mg
hair and the mean intra-assay variation is approximately
7.5%. All assays were performed without knowledge of
smoking habits.
Spirometry was carried out according to the European
Society Guidelines using the European Community for Steal
and Coal reference equations.17 AHR was evaluated by Mch
and AMP bronchial challenge, as described previously.18 In
brief, Mch (Lofarma, Milan, Italy) and AMP (Sigma Chemical
Co., St. Louis, MO, USA) were dissolved in PBS (pH 7.4) and
normal saline respectively to produce increasing doubling
concentrations (0.06–16mg/ml for Mch; 3125–800mg/ml for
AMP). Solutions were administered as aerosols generated
from a starting volume of 3ml in a disposable Inspiron
Minineb (C.R. Bard International, Sunderland, UK) driven by
compressed air at 8 l/min. Patients inhaled increasing
doubling concentrations of agonist in five breaths from
functional residual capacity to total lung capacity via a
mouthpiece and FEV1 measured at 1 and 3min after each
administration. The challenges were stopped when a
decrease of 20% in FEV1 had been achieved or when the
maximum concentration of agonist had been inhaled. The
bronchial responses to the inhaled agonists were expressed
as the provocative concentration causing a 20% decline in
FEV1 (PC20), which was calculated by linear interpolation
from the concentration–response curve constructed on a
logarithmic scale.
Sample size calculation for this study was based from
previous clinical pharmacological studies with Mch and AMP
bronchial challenges.10,16 Hence, sample size calculations
indicate that a total of 15 subjects will be required to detect
at least 1 doubling concentration difference between two
time periods with a power of 80% and using a significance
level of 5%. Allowing for possible drop out and considering
the SC rate of 30% in our clinic, the sample size was then
increased to a target of 55–60 subjects. As a 20% fall in FEV1
could not be obtained in a number of participants at the
highest concentration of agonists administered, a conserva-
tive estimate was obtained by assigning a value of twice thehighest concentration given. Because of these censored
data, this set of PC20 data could not be considered normal
and were compared for significance using non-parametric
statistical analysis.
For PC20 data available from participants who completed
all visits after SC, Friedman tests were used to compare
median PC20 values across all three time periods at once
(baseline, 6 and 12 months) with each agonist (AMP and Mch)
analysed separately. Non-parametric post hoc tests (i.e.
Wilcoxon’s Signed Ranks test) were then used to compare
median PC20 between pairs of time periods (baseline vs. 6
months, 6 vs. 12 months) if a significant difference in
medians between all three time periods was observed. As
the distribution of FEV1, FVC and FEF25–75 could be
considered to be normally distributed, repeated measures
ANOVA was used to compare mean FEV1, FVC and FEF25–75
values across all three time periods (baseline 6 and 12
months); each group of patients (quitters and relapsers) was
analysed separately. Paired t-tests were used to compare
mean values between pairs of time periods (baseline vs. 6
months, 6 vs. 12 months) if a significant difference in means
between all three-time periods was observed. The PC20 data
available from all smokers at baseline (every subject had an
uncensored value for both AMP and Mch PC20 in this data set)
were logarithmically transformed to improve normality and
linear regression was performed using the following pre-
dictors: age, gender and pack/years for each agonist
separately. Each predictor was assessed individually for its
ability to predict pack/years, and then multiple linear
regression was performed as appropriate. All analyses were
performed with the Statistical Package for Social Sciences
(SPSS Inc., Chicago, IL) for Windows version 12.0. A two-
tailed p-value of less than 0.05 was considered to indicate
statistical significance.Results
Throughout the SC program 27 subjects failed to return
for their follow-up visits. Thus, complete data were
available from 30 smokers with seasonal allergic rhinitis
(7asthma) after 1-year SC program, of which 16 quitters
and 14 SC failures. Asthma was also seen in association
with allergic rhinitis in three quitters and three relapsers.
Data from subjects who did not complete the study or
were lost to follow-up were not being included in the
analyses, with the exception of the baseline PC20 data
used to perform linear regression analyses. Descriptive
characteristics of this study population are outlined
in Table 1.
Abstinence from cigarette smoking was objectively con-
firmed at 6 and 12 months after admission in the SC
programme by biochemical validation of hair nicotine
(o5 ng/mg hair) and by eCO monitoring (o5 ppm). For the
sustained quitters, comparisons with baseline eCO and hair
nicotine values showed a significant and substantial reduc-
tion at 6 (Po0.001), and 12 months (Po0.001) after SC,
whereas no significant change were observed at any time
point in the SC failures. For those who successfully quitted,
the geometric mean eCO readings at baseline decreased
from 24.2 to 3.8 ppm at 6 months and to 3.1 ppm at 12
months. Likewise, the median hair nicotine value at baseline
ARTICLE IN PRESS
Table 1 Subjects’ characteristics at baseline.
Quitters Cessation failures Lost to follow up
No. of subjects 16 14 27
Sex (male:female ratio) 8:8 8:6 10:17
Age (yrs) 39.4 (74.4) 40.7 (72.9) 38.5 (74.0)
Duration of rhinitis (yrs) 9.7 (6–19) 11.0 (7–24) 10.3 (5–25)
No. of subjects with a diagnosis of asthma 3 3 –
FEV1 (% predicted) 90.5 (75,2) 92.0 (76,1) 89.2 (75,5)
FEV1/FVC 75.7 (72.6) 78.1 (72,4) 76.2 (73,3)
FEF25–75% (% predicted) 72.6 (76,9) 75.0 (76,1) 70.1 (77,9)
Geom. Mean (range) PC20 MCh (mg/ml) 2.88 (0.10–13.30) 4.08 (0.71–14.90) 3.54 (0.50–13.80)
Geom. Mean (range) PC20 AMP (mg/ml) 90.9 (9.6–377.6) 106.8 (9.7–319.7) 160.4 (21.3–445.2)
Pack/years 43.9 (79.0) 39.7 (711.1) 40.9 (712.5)
Exhaled CO (ppm) 24.2 (74.1) 27.5 (75.0) 23.0 (74.7)
Hair nicotine (ng/mg hair) 72.0 (42.2; 115.9) 79.5 (47.3; 134.5) 73.5 (41.0; 123.3)
FTND 6.3 (70.5) 6.7 (70.4) 6.8 (70.6)
AMP: adenosine 50-monophosphate.
Mch: methacholine.
CO: carbon monoxide.
FTND: Fagerstrom test for nicotine dependence.
Age, FEV1, FEV1/FVC, FEF2575%, pack/years, exhaled CO, and FTND are expressed as mean (7SEM) duration of rhinitis is expressed as
mean (range).
PC20 methacholine and PC20 AMP values are expressed as geometric mean (range).
Hair nicotine is expressed as median (inter-quartile range).
G. Piccillo et al.260decreased from 72.0 to 3.3 ng/mg hair at 6 months, and to
2.1 ng/mg hair at 12 months.
Intent-to-treat analyses, in which subjects not available
for the 12-month follow-up were considered SC failures,
found that 28% (16/57) of the participants had quit smoking
by the end of the study. It is likely that interventions in the
context of a research setting may well contribute to the high
rate of sustained cessation observed in this study.
For the quitters, comparisons with baseline PC20 AMP
values showed a significant difference both at 6 (P ¼ 0.006),
and 12 months (P ¼ 0.002) after SC, whereas no significant
change in PC20 AMP values was observed at any time point in
the SC failures. For those who successfully quitted, the
geometric mean PC20 AMP value at baseline increased
from 90.9mg/ml (range, 9.6–377.6mg/ml) to 203.8mg/ml
(range, 28.0–800.0mg/ml) at 6 months, and to 239.1mg/ml
(range, 30.0–800.0mg/ml) at 12 months (Table 2). When
changes in PC20 AMP values over time were expressed as
doubling dilutions, mean7SEM changes of 1.270.3, and
1.470.3 doubling concentrations were shown at 6 and 12
months, respectively (Figure 2A). For those who relapsed
during the SC program, the geometric mean PC20 AMP
values were 106.8mg/ml (range, 9.7–319.7mg/ml) at base-
line, 120.5mg/ml (range, 7.9–800.0mg/ml) at 6 months,
and 129.9mg/ml (range, 9.5–800.0mg/ml) at 12 months
(Table 2). Similar findings were obtained when asthmatics
(n ¼ 3) were excluded from analyses (data not shown).
For the quitters, comparisons with baseline PC20 Mch
values showed a significant difference only at 12 months
(P ¼ 0.002) after SC; no significant change in PC20 Mch
values was observed at any time point in the SC failures. For
those who successfully quitted, the geometric mean PC20
Mch value at baseline increased from 2.88mg/ml (range,
0.10–13.30mg/ml) to 3.87mg/ml (range, 0.16–16.00mg/ml)at 6 months, and to 6.04mg/ml (range, 0.24–16.00mg/ml)
at 12 months (Table 3). When changes in PC20 Mch values
over time were expressed as doubling dilutions, mean7SEM
changes of 0.470.2, and 1.170.2 doubling doses were
shown at 6 and 12 months, respectively (Figure 2B). For
those who relapsed during the SC program, the geometric
mean PC20 Mch values were 4.08mg/ml (range, 0.71–
14.90mg/ml) at baseline, 5.03mg/ml (range, 1.02–16.00
mg/ml) at 6 months, and 5.37mg/ml (range, 1.32–
16.00mg/ml) at 12 months (Table 3). Equivalent results
were obtained when asthmatics (n ¼ 3) were excluded from
analyses (data not shown).
For PC20 AMP, the model was found to be significantly
different from the null model (a model containing only a
constant term). About 70% of the variations in the data were
explained by the model containing age, gender and pack-
years. Pack/years was found to be significantly associated
with the level of AHR to AMP (Po0.001) (Figure 3A).
Subjects with high numbers of pack-years were found to
have lower values of PC20 AMP. Age and gender were not
found to be significant predictors of PC20 AMP after
controlling for the effect of pack-years. Residual analysis
showed two residuals had a z-value greater than 2 or less
than 2 (4%) which is acceptable. Residuals were also found
to be approximately normally distributed which is one of the
assumptions that regression is based on.
For PC20 Mch, the model was found to be just marginally
significantly different from the null model (P ¼ 0.042) with
only 11% of the variation in the data was explained by the
model containing age, gender and pack-years. Pack/years
was found to be a marginally significant predictor
(P ¼ 0.033) of PC20 Mch (Figure 3B). Age and gender were
not found to be significant predictors of PC20 Mch after
controlling for the effect of pack/years. Residual analysis
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Table 2 Individual PC20 AMP values before and after smoking cessation in quitters and cessation failures.
Quitters PC20 AMP (mg/ml) Cessation
failures
PC20 AMP (mg/ml)
Baseline 6 Months 12 Months Baseline 6 Months 12 Months
1 299.0 476.4 570.5 1 319.7 513.0 800.00
2 242.2 800.0 800.0 2 150.9 211.8 254.61
3 345.0 800.0 625.3 3 213.4 150.3 130.63
4 377.6 352.9 400.8 4 202.8 157.2 181.46
5 50.5 63.4 76.6 5 230.1 172.5 207.70
6 164.2 318.3 388.2 6 82.8 103.4 124.08
7 143.3 590.5 408.4 7 51.0 81.1 57.42
8 243.5 800.0 800.0 8 298.6 800.0 563.67
9 210.6 393.0 800.0 9 115.7 140.0 168.98
10 306.0 120.1 174.4 10 301.9 160.6 182.72
11 14.4 159.7 121.7 11 31.3 73.4 88.11
12 21.5 50.3 160.4 12 9.7 7.9 9.50
13 160.0 643.8 572.6 13 95.7 87.6 55.37
14 16.9 28.0 30.0 14 40.6 39.9 67.90
15 15.5 40.6 58.6
16 9.6 31.2 37.5
G.Mean 90.9 203.8 239.1 106.8 120.5 129.9
(Range) (9.6–377.6) (28.0–800.0) (30.0–800.0) (9.7–319.7) (7.9–800.0) (9.5–800.0)
AMP: adenosine 5’-monophosphate.
PC20 AMP values are expressed as geometric mean (range).
PC20 values in bold are for rhinitic subjects with asthma.
Figure 2 Individual changes in baseline PC20 AMP (A) and PC20 Mch (B) values 6 and 12 months after smoking cessation in quitters
(n ¼ 16) and smoking cessation failures (n ¼ 14). Changes in PC20 values from baseline (i.e. dotted line) are expressed as mean7SEM
doubling dilutions (D/D). Means are shown as horizontal bars. For AMP a significant difference (Po0.01) was observed both at 6 and
12 months after smoking cessation (quitters vs relapsers), whereas for Mch a significant change (Po0.01) was observed only at
12 months.
Changes in AHR after smoking cessation 261
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Table 3 Individual PC20 Mch values before and after smoking cessation in quitters and cessation failures.
Quitters PC20 MCh (mg/ml) Cessation
failures
PC20 MCh (mg/ml)
Baseline 6 Months 12 Months Baseline 6 Months 12 Months
1 12.10 6.58 8.95 1 10.50 7.08 8.45
2 2.15 3.67 4.97 2 3.21 6.07 7.20
3 10.86 16.00 16.00 3 4.31 7.12 8.04
4 13.30 9.96 16.00 4 8.80 16.00 12.22
5 2.67 2.26 7.12 5 12.30 9.22 16.00
6 3.85 8.64 6.84 6 2.30 9.44 7.39
7 2.25 3.05 6.63 7 2.80 4.49 5.48
8 10.40 16.00 16.00 8 14.90 16.00 9.53
9 1.04 2.98 3.58 9 2.30 2.05 1.94
10 5.37 8.36 10.30 10 4.02 5.30 6.36
11 5.10 4.80 16.00 11 7.55 3.80 4.50
12 4.05 12.16 10.06 12 0.71 1.02 1.32
13 4.50 5.66 9.96 13 4.72 3.21 3.81
14 0.10 0.16 0.24 14 1.02 1.59 1.59
15 0.66 1.03 2.42
16 0.71 0.50 1.56
G.Mean 2.88 3.87 6.04 4.08 5.03 5.37
(Range) (0.10–13.30) (0.16–16.00) (0.24–16.00) (0.71–14.90) (1.02–16.00) (1.32–16.00)
Mch: methacholine.
PC20 MCh values are expressed as geometric mean (range).
PC20 values in bold are for rhinitic subjects with asthma.
Figure 3 Univariate correlation of PC20 AMP (A) and PC20 Mch (B) values at baseline with number of pack/years in smokers with
allergic rhinitis (n ¼ 57). The strength of the association was assessed using Spearman’s rho. Although pack/years were found to be
significantly associated with the level of AHR to both AMP and Mch, the strength of the association was much stronger for AMP.
G. Piccillo et al.262showed 2 residuals had a z-value greater than 2 or less than
2 (4%) which is acceptable. Residuals were also found to
deviate slightly from a normal distribution. No significant
correlations were found between changes in PC20 AMP or in
PC20 Mch after SC and pack/years.
For the quitters, repeated measures ANOVA for FEF25–75%
values indicated that there was a highly significantdifference between all 3 time periods (Po0.001). Paired
t-tests did not show a significant difference between
baseline and 6 months (P ¼ 0.17) but did show a highly
significant difference between 6 and 12 months (Po0.001);
repeated measures ANOVA did not show a significant
difference between all three time periods (P ¼ 0.13) in
the SC failures. Repeated measures ANOVA for FEV1 and FVC
ARTICLE IN PRESS
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time periods in the study groups. Statistical analysis failed
to reveal any significant association between changes in PC20
AMP or in PC20 Mch after SC and spirometry data.Discussion
In the present study, we have shown improvement in AHR in
active smokers with seasonal allergic rhinitis with or without
asthma after SC. Our SC program resulted in a high rate
(approximately 30%) of sustained cessation among smokers
due to the intensity and duration of the program, along with
the extended use of pharmacological treatment together
with motivational interviewing. Though by the end of the
study changes in AHR to AMP and Mch improved to the same
extent, improvement in AHR 6 months after SC was observed
only for AMP and not Mch.
Intuitively one would expect that the intensity of smoking
is associated with the severity of AHR in smokers. Indeed,
we have also shown that the overall intensity of smoking
exposure (assessed as pack/years) is related to the severity
of AHR. In particular, the analysis of the cross-sectional data
has revealed that pack/years is more strongly associated
with AHR to AMP than Mch.
Early studies on the effect of SC on AHR to direct stimuli
in ‘healthy’ smokers have produced inconsistent find-
ings.19–22 This may be depending on a number of reasons
including the small number of subjects investigated, the
lack of suitable controls, and the nature of the provoking
stimulus used in bronchoprovocation protocols. Indeed, our
longitudinal study has shown substantial improvement in
AMP and Mch airways responsiveness 1-year after SC in
smokers for whom an objective proof of cessation was
obtained. Furthermore, one of the strength of the present
study is that the beneficial effects of SC in our quitters were
compared with individuals who relapsed thus strengthening
our conclusions that the observed improvement in AHR is a
consistent finding.
The observed improvement in AHR after SC has important
clinical implications. For instance, independently of their
smoking status, individuals with documented Mch reactivity
are known to be at risk for new onset asthma, cough
symptoms and decreased levels of pulmonary function.23–26
Moreover, we observed an increased risk (OR, 5.9) of new
onset asthma among current smokers compared to never
smokers and, in the multivariate model adjusting for other
asthma risk factors, this risk appeared to increase with each
pack/years unit.27 Thus, improving AHR in smokers can avoid
unnecessary morbidity.
Cross-sectional comparative studies in patients with COPD
have shown that smokers have similar levels of AHR to Mch
as ex-smokers,13,28,29 whereas the level of airway sensitivity
to inhaled AMP is reported to be more severe in smoking
than in ex-smoking COPD patients.13 This is in agreement
with recent observations in subjects with allergic rhinitis
who smoked; compared to nonsmokers, smokers exhibit a
much greater sensitivity to AMP.30 Unfortunately, the cross-
sectional methodology does not allow elucidating the
temporal nature of the relationship between cigarette
smoking and changes in AHR. The strength of evidence is
usually developed from prospective cohort studies and thepresent longitudinal study clearly illustrate that 6 months
after SC AHR to AMP is reduced to a larger degree compared
to Mch whereas changes in AHR improved to the same extent
for both AMP and Mch 12 months after smoking cessation.
These findings are to some extent compatible with those of a
recent longitudinal study in COPD patients, showing an
estimated two doubling concentrations improvement in AMP
and Mch responsiveness 1-year after SC in quitters with
COPD, with improvements in PC20 Mch being less consistent
than PC20 AMP.
31
The observation that SC at 6 months reduced sensitivity to
AMP, whereas no significant effect on AHR to direct stimuli
was observed, is novel. The explanation for the greater
effect of SC on AMP over Mch is not known, but must relate
to their different mechanism or mechanisms of action.
Whereas Mch acts directly on airway smooth muscle cells
via binding to muscarinic receptors, AMP appears to medi-
ate bronchoconstriction indirectly via stimulation of
specific adenosine A2B receptors on airway mast cells,
with subsequent release of preformed and newly formed
mediators.32
The observed improvement in AHR to AMP after SC might
result from a decrease in the number or in the activation
state of airway mast cells. Indeed, it has been demonstrated
that the number of mast cells in the bronchial biopsies
obtained from never smokers is much reduced compared to
asymptomatic smokers.33 Interestingly, the extensive mast
cell infiltration exhibited by asymptomatic smokers at all
levels of their bronchial mucosa was particularly predomi-
nant within the airway smooth muscle compartment.34
Smoke exposure has been shown to induce activation/
degranulation in airway resident mast cells35,36 and elevated
levels of histamine and tryptase have been measured in the
bronchoalveolar lavage fluid of active smokers.37 Besides
mast cell priming in vivo, it has been hypothesized that the
airways response to AMP may reflect the dynamic balance
between the distribution and affinity of the high affinity A2A
receptors and that of the low-affinity A2B receptors present
on mast cells.38 Indeed, cigarette smoking may upregulate
the activity of A2B receptors expressed in mast cells and
macrophages, as recently shown by Varani et al.39 in their
elegant work in COPD patients.
Cigarette smoke may also have a direct effect on airway
smooth muscle responsiveness. Experiments performed in
isolated human bronchi showed that constituents of cigar-
ette smoking altered airway smooth muscle responsiveness
in a dose-dependent manner.40 In guinea pigs, smoke
exposure significantly increased histamine induced bronch-
oconstriction but not acetylcholine induced bronchocon-
striction, indicating some specificity of the mediators
involved in the AHR triggered by smoke exposure.41 In
addition to affecting airway smooth muscle responsiveness
directly, smoking exposure can prime smooth muscle cells to
exogenous stimuli with enhanced AHR by releasing cytokines
and proteases from airway mast cells. There is ample
evidence that several mast cell mediators including tryptase
and TNFalfa may produce further sensitization of the airway
smooth muscle to a number of contractile stimuli.42,43
Whatever the mechanism accounting for the earlier
effect of SC on AMP over Mch, it is apparent that
responsiveness of the airways to inhaled AMP may be also
used as a sensitive indicator in smoke-induced inflammatory
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observation that the overall level of smoking exposure
(assessed as pack/years) is more strongly associated with
AHR to AMP than Mch at baseline.
FEF25–75% values at baseline indicate that a reduction in
maximum mid-expiratory flow rate—a spirometric manifes-
tation of small airways disease-is present in our study
population. This is not surprising considering that the
majority of participants were heavy smokers and all had
allergic rhinitis.44,45 Nonetheless, a novel observation from
the current study is that an improvement in FEF25–75% values
was observed at 12 months in those active smokers who
successfully completed the SC program whereas no change
was detected in the SC failures. This pattern of response is
similar to that described for PC20 Mch. However, statistical
analysis failed to reveal any significant association between
changes in PC20 Mch after SC and FEF25–75% data. Larger
clinical trials are required to shed more light on the
relevance of these findings in relation to smoking cessation.
Our prospective study in smokers with allergic rhinitis
(7asthma) now shows that SC can also improve AHR in
these individuals and this may confer some potential
clinical benefit.
Although this improvement was similar for both direct and
indirect agonists at the end of the study, an improvement at
6 months after SC was observed only for AMP but not Mch.
This suggests that monitoring of AHR to AMP might be an
accurate guide to detect earlier changes in AHR in smokers
during SC.
Despite its complexity, this research study should re-
inforce the public health imperative to decrease exposure to
tobacco products. If more successful strategies for prevent-
ing tobacco use could be developed, the burden of smoking-
related diseases in the population could be significantly
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